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ABSTRACT 
Mutations in the ClC-7/Ostm1 ion transporter lead to osteopetrosis and 
lysosomal storage disease. Its lysosomal localization hitherto precluded 
detailed functional characterization. Using a mutated ClC-7 that reaches the 
plasma membrane, we now show that both the amino-terminus and 
transmembrane span of the Ostm1 β-subunit are required for ClC-7 Cl-/H+-
exchange, whereas the Ostm1 transmembrane domain suffices for its ClC-
7-dependent trafficking to lysosomes. ClC-7/Ostm1 currents were strongly 
outwardly rectifying owing to slow gating of ion exchange which itself 
displays an intrinsically almost linear voltage-dependence. Reversal 
potentials of tail currents revealed a 2Cl-/1H+ exchange stoichiometry. 
Several disease-causing CLCN7 mutations accelerated gating. Such 
mutations cluster to the second cytosolic CBS domain and potential 
contact sites at the transmembrane segment. Our work suggests that 
gating underlies the rectification of all endosomal/lysosomal CLCs and 
extends the concept of voltage-gating beyond channels to ion exchangers. 
 
Key words: chloride channel / trafficking / structure-function / antiport / 
conductance 
 
CLC anion transport proteins (Jentsch, 2008), first identified by the cloning of the 
Cl--channel ClC-0 from Torpedo (Jentsch et al, 1990), associate to dimers of 
identical or closely related subunits. Each CLC subunit contains an ion 
translocation pathway that is largely independent from the other subunit (Dutzler 
et al, 2002; Lorenz et al, 1996; Ludewig et al, 1996; Middleton et al, 1996; 
Robertson et al, 2010; Weinreich & Jentsch, 2001). Some CLC channels, 
however, display ‘common gating’ of both pores (Accardi & Pusch, 2000; Bauer 
et al, 1991; Miller & White, 1984). Eukaryotic CLC proteins have large cytosolic 
carboxyterminal domains comprising two CBS (cystathionine-β-synthase) 
domains that in some cases can bind nucleotides like ATP (Meyer et al, 2007) 
and have a poorly understood role in gating (Bykova et al, 2006; Estévez et al, 
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2004; Fong et al, 1998; Zhang et al, 2008; Zifarelli & Pusch, 2009b). Crystal 
structures of bacterial (Dutzler et al, 2002) and algal (Feng et al, 2010) CLC 
proteins, and of CBS domains from vertebrate CLCs (Markovic & Dutzler, 2007; 
Meyer & Dutzler, 2006; Meyer et al, 2007), have yielded important insights on 
how their structure relates to their biophysical properties. 
Intriguingly, the CLC gene family comprises both Cl- channels and electrogenic 
Cl-/H+-exchangers (Jentsch, 2008). The border between these different transport 
classes, however, is blurred, as gating of the ClC-0 Cl- channel may involve the 
transport of a proton (Lisal & Maduke, 2008) and because certain anions can 
uncouple anion flux from proton countertransport (Bergsdorf et al, 2009; 
Nguitragool & Miller, 2006; Zdebik et al, 2008; Zifarelli & Pusch, 2009a). 
Moreover, transport activity of mammalian ClC-3 to ClC-6 Cl-/H+-exchangers is 
strongly voltage-dependent (Friedrich et al, 1999; Li et al, 2002; Neagoe et al, 
2010; Steinmeyer et al, 1995). Their almost instantaneous deactivation at 
negative voltages precludes measurements of tail currents and it remains 
unresolved whether their voltage-dependence results from a voltage-sensitivity of 
the exchange process per se or from turning the transporter ‘on’ and ‘off’ 
(‘gating’) (Hebeisen et al, 2003; Picollo et al, 2010; Smith & Lippiat, 2010; Zdebik 
et al, 2008).  
Mammalian endosomal/lysosomal Cl-/H+-exchangers (ClC-3 to ClC-7) regulate 
vesicular H+ and Cl- concentration (Jentsch, 2007; Novarino et al, 2010; Weinert 
et al, 2010). Disruption of endosomal ClC-5 impairs renal endocytosis (Piwon et 
al, 2000) in Dent’s disease (Lloyd et al, 1996), whereas mutations in lysosomal 
ClC-7 entail osteopetrosis and lysosomal storage disease (Kasper et al, 2005; 
Kornak et al, 2001). Similar phenotypes were observed when uncoupling point 
mutations converted these exchangers into pure anion conductors (Novarino et 
al, 2010; Weinert et al, 2010). ClC-7 needs Ostm1 as β-subunit for protein 
stability (Lange et al, 2006). Hence disruption of Ostm1 results in osteopetrosis 
(Chalhoub et al, 2003) and lysosomal pathology (Lange et al, 2006; Pressey et al, 
2010) just like a loss of ClC-7. It has remained unclear which parts of Ostm1 
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interact with ClC-7 and whether Ostm1 not only stabilizes ClC-7, but also 
modulates its ion transport activity. 
Apart from the acid-secreting membrane of osteoclasts (Kornak et al, 2001; 
Lange et al, 2006), ClC-7/Ostm1 is absent from the plasma membrane, severely 
limiting its biophysical characterization. Transport studies of native lysosomes 
(Graves et al, 2008; Weinert et al, 2010) suggest that ClC-7 mediates Cl-/H+-
exchange. However, no currents could be measured, essential properties like 
voltage-dependence, kinetics and substrate specificity have remained unknown, 
and no structure-function analysis could be performed. Here we exploit the partial 
plasma membrane expression of recently described ClC-7 mutants which 
disrupted cytosolic sorting motifs (Stauber & Jentsch, 2010) to characterize the 
biophysical properties of ClC-7 and its functional interaction with Ostm1. The 
slow deactivation of ClC-7/Ostm1 resulted in tail currents that revealed functional 
features that could not be studied with other CLC anion/proton exchangers.   
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RESULTS 
Basic characterization of ClC-7/Ostm1 Cl-/H+-exchange 
Disrupting two dileucine lysosomal sorting motifs in the cytosolic N-terminus of 
rat ClC-7 (rClC-7) partially redirects the mutant protein (rClC-7LL23/24AA,LL36/37AA, in 
short rClC-7PM) to the plasma membrane (Stauber & Jentsch, 2010). Likewise 
human ClC-7 (hClC-7) carrying the mutations LL23/24AA and LL68/69AA (hClC-
7PM) partially traffics to the plasma membrane, as ascertained in a 
chemiluminescence assay for an added extracytosolic HA-tag (Figure 1A). This 
assay failed to detect hClC-7PM when co-expressed with Ostm1, possibly owing 
to a shielding of the epitope by the highly glycosylated N-terminus of Ostm1 
(Lange et al, 2006). Indeed, both rClC-7PM/Ostm1 and hClC-7PM/Ostm1 gave 
robust plasma membrane currents (Figure 1B,C for rClC-7PM, and 
Supplementary Figure S1A for hClC-7PM). Since currents of human and rat ClC-
7PM were indistinguishable in both Xenopus oocytes and transfected mammalian 
cells, we refer to both as ClC-7PM in the following. 
Expression of ClC-7PM/Ostm1 in Xenopus oocytes (Figure 1B,C and 
Supplementary Figure S1A), tsA201 or HeLa cells (Supplementary Figure S1B) 
yielded strongly outwardly rectifying currents that activated slowly at voltages 
more positive than ~ +20 mV. In stark contrast to ClC-3 through ClC-6 (Friedrich 
et al, 1999; Li et al, 2002; Matsuda et al, 2008; Neagoe et al, 2010), full activation 
was not even observed after several seconds and slow deactivation resulted in 
tail currents at negative voltages (Figure 1C (arrow) and Supplementary Figure 
S1A,B). Whole-cell patch-clamp experiments in HeLa cells showed that ClC-
7PM/Ostm1 currents do not require intracellular ATP (Supplementary Figure S1C). 
We neither observed significant changes in current amplitudes like described for 
ClC-5 (Zifarelli & Pusch, 2009b) which is known to bind ATP by its CBS domains 
(Meyer et al, 2007), nor changes in voltage-dependence. 
As typical for CLC antiporters (Bergsdorf et al, 2009; Dutzler et al, 2003; 
Friedrich et al, 1999; Li et al, 2002; Neagoe et al, 2010; Picollo & Pusch, 2005; 
Scheel et al, 2005; Zdebik et al, 2008), mutating the ‘gating glutamate’ (E245 in 
rat) of ClC-7PM to alanine resulted in almost ohmic, time-independent currents, 
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and changing the ‘proton glutamate’ (E312 in rat) to alanine reduced currents to 
background levels (Figure 1B,C and Supplementary Figure S1A). ClC-7PM/Ostm1 
mediated Cl-/H+-exchange as evident from depolarization-induced intracellular 
alkalinization of Xenopus oocytes expressing these proteins (Figure 1D). In these 
‘Fluorocyte’ experiments, the pH-dependent fluorescence of BCECF previously 
injected into oocytes provides a semi-quantitative measure of cytosolic pH 
changes in response to depolarizing voltage-steps. Depolarization not only 
activates ClC-7PM/Ostm1, but also provides a driving force for coupled H+-exit/Cl--
entry. Outward transport of protons required extracellular Cl- (Figure 1E), could 
occur against its electrochemical gradient (pHo=5.5, Figure 1E), and was 
abolished by either the E245A or the E312A mutation (Figure 1D). ClC-
7PM/Ostm1 currents decreased upon replacing extracellular Cl- by I-, but unlike 
ClC-4 and -5 (Friedrich et al, 1999), currents were not larger with NO3- (Figure 
2A). Replacing a Cl--coordinating serine by proline (rClC-7(S202P)) increased 
the nitrate/chloride conductance ratio as with other CLC antiporters (Bergsdorf et 
al, 2009; Neagoe et al, 2010; Zifarelli & Pusch, 2009a) and with ClC-0 (Bergsdorf 
et al, 2009; Picollo et al, 2009). Akin to ClC-4, -5 and -6 (Friedrich et al, 1999; 
Neagoe et al, 2010; Picollo et al, 2010), currents were decreased by acidic 
extracellular pH (Figure 2B). In addition to a diminished driving force for Cl-/H+-
exchange with increased extracellular [H+], faster activation kinetics at more 
alkaline pHo contributes to the pH-dependence of ClC-7PM/Ostm1 outward 
currents (Figure 2C). Voltage-dependent current activation was also strongly 
dependent on temperature (Figure 2D). Mono-exponential fits yielded activation 
rate constants of 2.8 ± 0.2 s-1 at 21°C and 16.6 ± 1.9 s-1 at 37°C, giving an 
estimate of Q10 ≈ 3. 
 
Slow ClC-7/Ostm1 gating allows characterization of an ‘open exchanger’ 
The slow deactivation of ClC-7PM/Ostm1 currents provides a unique opportunity 
to study mammalian Cl-/H+-exchange at negative membrane voltages. Using 
protocols developed for ion channels, we activated (‘opened’) ClC-7PM/Ostm1 by 
positive prepulses and measured tail currents from transfected HeLa cells at 
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different test voltages (Figure 3A). We increased tail current amplitudes by 
including 121 mM Cl- in the patch pipette. Tail currents were extrapolated to the 
beginning of the test pulse to obtain the voltage-dependence of ‘open exchanger’ 
currents (Figure 3A). Contrasting with the strong voltage dependence of pseudo-
steady-state currents, ‘open exchanger’ currents displayed only very slight 
outward rectification. 
Whereas the strong rectification and near-instantaneous deactivation of ClC-4 
and ClC-5 precludes measurements of reversal potentials (Friedrich et al, 1999; 
Steinmeyer et al, 1995), ClC-7PM/Ostm1 tail currents allowed us to determine Cl-
/H+-coupling ratios from Cl-- and H+-dependent shifts in reversal potentials 
(Figure 3B). Our results were best fitted by a 2Cl-:1H+ stoichiometry. The 
apparent deviation from this stoichiometry at nominal pHo of 8.4 might be 
explained by depolarization-induced outward transport of protons through the 
exchanger (Zifarelli & Pusch, 2009a). This process is expected to cause a larger 
deviation of actual from nominal pH at the lower H+-concentrations of more 
alkaline pH.  
Whereas the tail current analysis of instantaneous ‘open exchanger’ currents 
requires the same open probability popen at the beginning of test pulses (as 
indicated above by identical macroscopic currents), popen must have reached 
steady-state at the respective voltage when popen is determined as a function of 
voltage by tail currents. The slow voltage-dependent activation of ClC-7PM/Ostm1, 
however, precluded reliable measurements of steady-state currents that are 
needed for this analysis. We therefore resorted to a ClC-7 point mutant (R762Q; 
described below) that drastically accelerates activation. ClC-7PM(R762Q)/Ostm1 
currents reached steady-state already ~400 ms after the beginning of voltage 
steps (Figure 3C). At t = 500 ms, tail currents were measured at a constant test 
voltage (+80 mV) as function of the voltage of the preceding pulse (between -40 
and +140 mV). After correcting for endogenous HeLa cell currents, apparent 
popen(V) was obtained by extrapolating tail currents to the time of the voltage step 
(see Methods). Boltzmann fits (Figure 3D) revealed a voltage of half-maximal 
activation V½ ≈ 82  mV and an apparent gating charge of zn ≈ 1.32. Although we 
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performed this tail analysis study with a mutant, we expect the values of ‘WT’ 
ClC-7/Ostm1 to be similar. 
 
Structural basis and functional consequences of Ostm1-ClC-7 interactions 
So far, all experiments on ClC-7PM were performed in co-expression with Ostm1. 
When we expressed ClC-7PM with or without Ostm1 in HeLa cells 
(Supplementary Figure S1D) or Xenopus oocytes (not shown), ClC-7PM yielded 
currents only together with Ostm1. Since ClC-7PM clearly reaches the plasma 
membrane also without Ostm1 (Figure 1A and (Stauber & Jentsch, 2010)), these 
results indicate that Ostm1 is needed to activate ClC-7 ion transport.  
We next asked which parts of Ostm1 interact with ClC-7. We constructed 
chimeras with CD4, a protein that shares the type I transmembrane topology of 
Ostm1 (Lange et al, 2006) but traffics to the plasma membrane by default. The 
extracellular, transmembrane, and intracellular domains of Ostm1 were replaced 
by those of CD4 either individually or in combination. Without ClC-7, Ostm1 stays 
in the endoplasmic reticulum (ER), whereas a portion of Ostm1 reaches 
lysosomes upon co-expression with ClC-7 (Lange et al, 2006). We first 
ascertained that Ostm1 and Ostm1/CD4 chimeras carrying C-terminal GFP-tags 
were confined to the ER and/or plasma membrane of transfected HeLa cells 
(Figure 4A). We then co-transfected GFP-tagged Ostm1/CD4 chimeras with ClC-
7 and assayed the co-localization of GFP fluorescence with the lysosomal 
marker LAMP-1 as read-out for Ostm1-ClC-7 interaction (Figure 4B,C and 
Supplementary Figure S2). The transmembrane domain (TMD) of Ostm1 was 
necessary and sufficient for Ostm1 constructs being carried to lysosomes by 
ClC-7 (Figure 4C).  
While these experiments suggested that the TMD of Ostm1 binds ClC-7, other 
parts of Ostm1 may modulate ClC-7 transport activity. We therefore assayed 
currents of Xenopus oocytes co-expressing ClC-7PM and Ostm1/CD4 chimeras 
(Figure 4D). As expected from our localization assay, currents were not 
detectable when the TMD of Ostm1 was replaced by that of CD4. Even larger 
currents were observed when ClC-7PM was co-expressed with a chimera (OOC) 
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in which the Ostm1 C-terminus was replaced by that of CD4. By contrast, 
currents were indistinguishable from background with chimeras lacking the 
Ostm1 N-terminus (Figure 4D), even though ClC-7PM was still able to reach the 
plasma membrane (Supplementary Figure S3). Hence both the N-terminus and 
TMD of Ostm1 are required for ClC-7 transport activity.  
 
 
Functional effects of human CLCN7 mutations underlying osteopetrosis 
The plasma membrane expression of ClC-7PM/Ostm1 allowed us for the first time 
to study functional consequences of disease-causing CLCN7 mutations (Cleiren 
et al, 2001; Frattini et al, 2003; Kornak et al, 2001; Letizia et al, 2004; Pangrazio 
et al, 2010; Phadke et al, 2010; Waguespack et al, 2003), which we selected 
from different categories based on the mode of inheritance (recessive vs. 
dominant) and on their location within the protein (transmembrane region or 
cytoplasmic CBS domain) (Figure 5A and Supplementary Figure S4).  
Within all CLCN7 mutation categories mentioned above we found mutations that 
abolished or strongly reduced currents (Figure 5C and Supplementary Figure 
S5A). Surprisingly, other mutations either left ClC-7PM currents virtually 
unchanged (e.g. S744F (Frattini et al, 2003)) or accelerated their activation 
kinetics between moderately (e.g. the frameshift mutation G796fs (Cleiren et al, 
2001)) and dramatically (e.g. R762Q (Kornak et al, 2001)) (Figure 5C, 
Supplementary Figure S5A). Mutants that yielded plasma membrane currents 
also transported H+ as revealed by Fluorocyte (Zdebik et al, 2008) experiments 
(not shown). To test whether changed subcellular targeting of ClC-7/Ostm1 might 
explain the disease-causing effect of those mutants, we inserted them into hClC-
7 instead of hClC-7PM and co-expressed them with GFP-tagged Ostm1 in HeLa 
cells. However, in addition to a pronounced ER-like labelling, all mutants that 
gave currents (in hClC-7PM) reached their normal destination (lysosomes) where 
they co-localized with Ostm1 (Figure 5D and Supplementary Figure S5B). Only 
three of the mutants with reduced currents were retained in the ER, whereas the 
other six partially localized with Ostm1 to late endosomes/lysosomes (Figure 5D 
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and Supplementary Figure S5B). In the absence of lysosomal targeting 
sequences, ClC-7 reaches the plasma membrane by default once it has left the 
ER (Stauber & Jentsch, 2010). Hence normal lysosomal targeting (in hClC-7) of 
the V297M, F318L, L490F, L651P, R767P and R767W mutants, all of which 
reduce or abolish plasma membrane currents in hClC-7PM, suggests that these 
mutations may interfere directly with the ion transport of ClC-7 or with the 
mechanism by which Ostm1 activates ClC-7. One should note, however, that all 
these mutants were able to carry Ostm1 to lysosomes. A reduction in the 
expression level due to limited stability may also contribute to reduced currents. 
Western blot analysis showed that this was not the case for the V297M and 
F318L mutants, whereas protein levels were markedly reduced with the L490F 
mutant (Supplementary Figure S6). 
 
 
 
 
DISCUSSION 
Despite the medical importance of ClC-7/Ostm1 and its crucial role in lysosomal 
function (Kasper et al, 2005; Kornak et al, 2001; Lange et al, 2006; Wartosch et 
al, 2009; Weinert et al, 2010), the only available information concerning its 
biophysical properties has remained its ability to perform Cl-/H+-exchange 
(Graves et al, 2008; Weinert et al, 2010). Acid-activated currents previously 
ascribed to ClC-7 (Diewald et al, 2002) most likely represent currents 
endogenous to the expression systems (Jentsch, 2008). Exploiting the partial 
plasma membrane localization of ClC-7 mutants which we have recently 
described (Stauber & Jentsch, 2010), we could now study for the first time 
important details of ion transport properties, investigate effects of human 
disease-causing mutations, and show that ClC-7 needs specific domains of the 
Ostm1 β-subunit not only for protein stability (Lange et al, 2006), but also for ion 
transport activity. 
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Voltage-gating of intrinsically linear voltage-dependent 2Cl-/H+-exchange  
Several properties of ClC-7/Ostm1 described here have recently emerged as 
being typical for mammalian CLC exchangers (Jentsch, 2008). This includes the 
preference of Cl- over I-, decreased transport activity with acidic external pH, 
strong outward rectification, and effects of neutralizing ‘gating’ and ‘proton’ 
glutamates which result in an uncoupling of anion movement from protons and 
an apparent abrogation of all ion transport, respectively.  
While ClC-7/Ostm1 differs from ClC-3 to -6 with respect to NO3- selectivity, the 
most important biophysical difference to those transporters is the slow voltage-
dependent activation and deactivation of ClC-7/Ostm1. Whereas ClC-4 and -5 
show a similarly steep voltage-dependence with significant currents being 
observable only at positive voltages, a major component of the current activated 
upon depolarization appears instantaneous, with the remaining <30% reaching 
steady-state in less than ~100 ms (Friedrich et al, 1999; Steinmeyer et al, 1995). 
Despite the drastic difference in gating kinetics, the V½ of ClC-
7PM(R762Q)/Ostm1 (~82 mV) agrees well with that of ClC-4 measured in the 
presence of uncoupling anions (Orhan et al, 2011). Most importantly, currents of 
ClC-4 and ClC-5 deactivated almost instantaneously at negative voltages, with 
no tail currents being detectable (Friedrich et al, 1999; Steinmeyer et al, 1995). 
Therefore, it was impossible to determine whether their Cl-/H+-exchange can 
function, in principle, also at negative voltages (i.e. lumen-positive for vesicles). 
ClC-7/Ostm1 currents, by contrast, did not reach steady-state even after more 
than 2 seconds. We have avoided using longer pulses to minimize confounding 
local changes in Cl-- and H+-concentrations. Although deactivation upon stepping 
back to negative potentials was faster than activation, it resulted in respectable 
tail currents, in particular when [Cl-]i was kept high in whole-cell patch-clamp 
measurements. Currents at negative voltages clearly demonstrated that net Cl-
/H+-exchange can occur in both directions, which has not been demonstrated 
previously for any mammalian CLC. Instantaneous tail currents displayed an 
almost linear dependence on voltage. As their slight outward rectification might 
be owed to the difference in [H+] and [Cl-] on both sides of the membrane, we 
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propose that the intrinsic Cl-/H+-exchange rate is nearly linearly related to the 
driving force. This hypothesis needs to be tested in future studies under a 
broader range of conditions. The almost ohmic tail currents also indicate that the 
model of (Zdebik et al, 2008), in which the voltage-dependence of ClC-5 may be 
related to a voltage-driven transport of cytosolic H+ to the central exchange site, 
does not apply for ClC-7/Ostm1. It has also been questioned for ClC-5 (Picollo et 
al, 2010). 
We conclude that voltage-dependence of ClC-7/Ostm1 is almost exclusively 
caused by a slow activation/deactivation process that we like to refer to as 
‘gating’ in analogy to the terminology used for ion channels. CLC Cl- channels 
have two kinds of gates, one for each pore of the (homo)dimeric channel (the 
‘protopore gate’, which relates to the ‘gating glutamate’), and a less well 
understood ‘common gate’ that acts on both pores simultaneously (Jentsch, 
2008). In the Torpedo channel ClC-0, the protopore gate is fast and has a Q10 of 
~2.2, whereas the common gate is slow with a Q10 of ~40 (Pusch et al, 1997). 
However, protopore and common gates of the mammalian muscle Cl- channel 
ClC-1 display Q10 values of ~3 and ~4, respectively (Bennetts et al, 2001). 
Therefore, the Q10 of ClC-7/Ostm1 activation cannot serve as criterion for 
deciding whether the underlying process is analogous to protopore or common 
gating.  
The majority of those human CLCN7 mutations found to accelerate the ‘gating’ of 
ClC-7/Ostm1 affect residues in the ClC-7 C-terminus. Two of these residues 
(R762 and R767) are located at the surface of the second CBS domain in close 
proximity to the transmembrane part as revealed by the X-ray structure of algal 
CmClC (Feng et al, 2010). Intriguingly, two other ‘accelerating’ mutations (L213F 
and R286Q) affect residues in the membrane part which are in close proximity to 
CBS2 (Figure 5B and Supplementary Video 1). 
Hence the slow gating of ClC-7/Ostm1 may involve interactions of CBS2 with the 
transmembrane part of ClC-7. As the cytoplasmic C-termini were implicated in 
‘common gating’ of ClC-0 (Bykova et al, 2006; Estévez et al, 2004; Fong et al, 
 13
1998), these observations indirectly suggest that ClC-7/Ostm1 activity is 
regulated by a ‘common gate’. 
Voltage-dependence was abolished by the uncoupling mutation E245A as in 
other CLC transporters (Bergsdorf et al, 2009; Friedrich et al, 1999; Neagoe et al, 
2010; Picollo & Pusch, 2005; Scheel et al, 2005). This result is compatible with 
the notion that E245, which may change its position during 2Cl-/H+-exchange 
cycles (Feng et al, 2010), acts as a ‘gate’. The short distance which its negative 
side chain may move in the electric field, however, seems to exclude a function 
as voltage-sensor as it would result in an apparent ‘gating charge’ much smaller 
than 1. The apparent gating valence determined here for ClC-7PM(R762Q)/Ostm1 
(zn ≈ 1.32) agrees well with that of ClC-4 in the presence of uncoupling anions 
(Orhan et al, 2011) and with gating charges determined for ClC-0 (Bauer et al, 
1991; Hanke & Miller, 1983; Pusch et al, 1995), ClC-1 (Pusch et al, 1994) and 
ClC-2 (de Santiago et al, 2005) Cl- channels. We envisage a conformational 
change, possibly involving cytosolic CBS domains, that fixes the position of E245 
‘gating glutamate’, thereby resulting in a ‘closed state’ of the transporter. Whether 
the ‘gating charge’ is supplied by permeant ions (Lisal & Maduke, 2008; Pusch et 
al, 1995), intrinsic charges of the protein, or a combination thereof (Smith & 
Lippiat, 2010), remains an open question. 
The tail currents of ClC-7/Ostm1 provided the unique possibility to determine the 
Cl-/H+-exchange stoichiometry from reversal potentials. These cannot be 
measured reliably with other endosomal/lysosomal CLC exchangers. Our data 
were best fit by a 2Cl-:1H+ stoichiometry as originally described for the 
prokaryotic EcClC-1 (Accardi & Miller, 2004) and which might be rationalized in 
terms of a switch in the position of the ‘gating glutamate’ (Feng et al, 2010).  
It is intriguing that ClC-7/Ostm1, just like the other vesicular CLC Cl-/H+-
exchangers (Friedrich et al, 1999; Li et al, 2002; Neagoe et al, 2010; Steinmeyer 
et al, 1995), displays such strong voltage dependence. This rectification is not an 
inevitable consequence of the Cl-/H+-exchange per se, as our measurements of 
‘open transporter’ currents have shown. This suggests that the rectification might 
have a physiological importance, which, however, remains obscure. The strong 
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outward rectification of ClC-4 and -5 has puzzled the field for a long time 
because it implies that these transporters are almost inactive in inside-positive 
endosomes (Jentsch, 2007; Jentsch et al, 2002). However, recent model 
calculations showed that vesicles may attain an inside-negative voltage through 
the activity of 2Cl-/H+-exchangers (Weinert et al, 2010).  
 
Transmembrane domain and exoplasmic N-terminus of Ostm1 are needed 
for ClC-7 ion transport activity 
ClC-7 is the only CLC exchanger known to need an accessory subunit (Lange et 
al, 2006). This β-subunit, Ostm1, is a small type I transmembrane protein with a 
highly glycosylated N-terminus (Lange et al, 2006) that was identified as being 
truncated in the osteopetrotic grey lethal mouse (Chalhoub et al, 2003). The 
pathology resulting from a loss of Ostm1 was explained by the concomitant loss 
of ClC-7 which is unstable without its β-subunit (Lange et al, 2006). Our work 
now shows that Ostm1 is also needed for the ion transport activity of ClC-7. 
Hence the low levels of ClC-7 (~5% of WT protein) remaining in tissues of 
Ostm1-/- mice (Lange et al, 2006) are non-functional. Disruption of Ostm1 leads 
to a complete loss of ClC-7 ion transport. 
To elucidate which parts of Ostm1 interact with ClC-7, we assayed the ClC-7-
dependent trafficking of Ostm1 to lysosomes, an assay that turned out to be 
more reliable than co-immunoprecipitation (Lange et al, 2006). The single TMD 
of Ostm1 was necessary and sufficient for correct trafficking, suggesting that 
Ostm1-ClC-7 binding involves interactions between transmembrane helices of 
both ClC-7 and Ostm1. Consistent with the lack of interaction in the trafficking 
assay, a chimera in which the Ostm1 TMD was replaced by that of CD4 failed to 
activate ClC-7PM ion transport. Surprisingly, ClC-7PM transport activity also 
required the highly glycosylated extracytosolic aminoterminus of Ostm1. 
Normally Ostm1 is cleaved proteolytically in (or on its way to) lysosomes, but the 
cleavage products are still bound together by disulfide bonds (Lange et al, 2006). 
Since it is unlikely that ClC-7PM/Ostm1 reaches the plasma membrane through a 
prelysosomal/lysosomal compartment, our results provide circumstantial 
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evidence that cleavage of Ostm1 is not needed for its ability to stimulate ion 
transport of ClC-7. The cytosolic C-terminus of Ostm1 was not needed, although 
we cannot exclude that it modulates ClC-7 transport as hinted at by the larger 
currents induced by the OOC chimera. Barttin, a protein that only interacts with 
ClC-K Cl- channels (Estévez et al, 2001), is the only other β-subunit of CLC 
proteins known to date. Like Ostm1, barttin is thought to bind to ClC-K α-subunits 
through its transmembrane domains (Scholl et al, 2006; Tajima et al, 2007), but 
activation of ion transport requires its intracellular carboxy-terminus (Scholl et al, 
2006). 
 
Effects of disease-causing CLCN7 mutations  
Roughly forty different mutations in CLCN7 have been found in humans suffering 
from osteopetrosis, from which we have selected 18 for the present analysis. No 
consistent differences concerning their effects on ion transport or trafficking were 
found when comparing recessive and dominant, or membrane- and CBS-domain 
localized mutations. As expected, several mutants yielded reduced currents, and 
in others voltage-activated currents were not detectable. G240R, G521R and 
R526W, all of which alter charges in a transmembrane domain, led to retention in 
the ER irrespective of co-expression with Ostm1. Like previously reported for the 
G215R mutant (Schulz et al, 2010), however, some mutants overcame ER 
retention when co-expressed with Ostm1 (data not shown). Several mutations 
reduced or abolished currents although normal lysosomal targeting (when 
inserted into hClC-7/Ostm1) indirectly indicated that they reached the plasma 
membrane in hClC-7PM/Ostm1.  
Surprisingly, half of the disease-causing mutations gave currents when studied in 
ClC-7PM/Ostm1. In many cases these currents showed accelerated kinetics of 
activation, such as L213F, R286Q, R762Q, R762L, and R767Q. When 
expressed in HeLa cells together with Ostm1, these mutants (in hClC-7) could 
reach lysosomes. This raises the question whether the slow activation kinetics of 
ClC-7/Ostm1 is needed for its physiological function. However, trafficking and 
protein stability might be different in vivo as compared to heterologous 
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overexpression. Indeed, Western blots and immunofluorescence previously failed 
to detect ClC-7 protein in fibroblasts from a patient heterozygous for an early 
stop codon in CLCN7 and the ‘accelerating’ R762Q mutation (Kornak et al, 2001). 
 
Conclusions and outlook 
While ClC-7 shares many biophysical properties with the other mammalian CLC 
Cl-/H+-exchangers, it is unique in that it needs a β-subunit (Ostm1) and that its 
activation and inactivation by voltage is much slower.  
Whereas an interaction through transmembrane domains, as observed here for 
ClC-7/Ostm1, is not without precedent (Scholl et al, 2006; Tajima et al, 2007), the 
apparently strict dependence of ion transport activity on the highly glycosylated 
Ostm1 N-terminus (Lange et al, 2006) is surprising. It raises the question 
whether sugar moieties on Ostm1 interact with the rather limited extracytosolic 
part of the ClC-7 protein and how this activates ion transport. This activation 
might involve the same gating mechanism that ‘opens’ and ‘closes’ ClC-7/Ostm1 
like an ion channel – the difference being that it is not a purely diffusive pore, but 
ion exchange which is ‘gated’. It is intriguing that ClC-7/Ostm1 is the only 
endosomal/lysosomal CLC which is gated so slowly and that several disease-
causing missense mutations in the ClC-7 CBS2 domain accelerate its activation. 
Interestingly, there is not even one missense mutation in a CBS domain among 
the many CLCN5 mutations identified so far in Dent’s disease (Jentsch, 2008; 
Lloyd et al, 1996). Together with the fact that ClC-5 activates and deactivates 
much faster, these observations suggest that the sluggish voltage-dependence of 
ClC-7/Ostm1 might play a physiological role. This seems surprising in view of its 
localization to the non-excitable membranes of lysosomes and the osteoclast 
ruffled border, but abrupt voltage-changes that would not significantly ‘open’ ClC-
7/Ostm1 seem possible – for instance, in second-messenger induced release of 
Ca++ from lysosomes.  
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FIGURE LEGENDS 
 
Figure 1 Basic characterization of ClC-7PM/Ostm1 in Xenopus oocytes. (A) 
Chemiluminescence assay for surface detection of hClC-7 and hClC-7PM with an 
extra-cytosolic HA-tag. hClC-7PM-exHA, but not hClC-7-exHA is detected at the 
surface of Xenopus oocytes. Co-expression with Ostm1 suppresses the 
luminescence signal although ClC-7PM/Ostm1 yields plasma membrane currents 
(in B,C). Mean luminescence intensity (error bars, s.e.m.) normalized to hClC-
7PM-exHA from 4 independent experiments. (B, C) Two-electrode voltage-clamp 
analysis in Xenopus oocytes. Representative voltage-clamp traces (C) of rClC-
7PM (‘WT’), rClC-7PM(E245A) and rClC-7PM(E312A) co-expressed with Ostm1. 
Arrow indicates tail currents. Voltage was clamped from -80 to +80 mV in 2-sec 
steps of 20 mV (inset). Mean ± s.e.m. of currents reached after 2 sec plotted (B) 
as function of voltage (rClC-7PM, n=20; rClC-7PM(E245A), n=13; rClC-7PM(E312A), 
n=11; uninjected, n=16 oocytes from at least 3 batches). Virtually identical results 
were obtained with hClC-7PM (Supplementary Figure 1A). (D, E) Intracellular pH 
changes of Xenopus oocytes co-expressing rClC-7PM (‘WT’ or glutamate 
mutants) with Ostm1 in response to a 10-sec depolarization. Top traces, clamp 
currents; bottom traces, pH-dependent BCECF fluorescence measured with the 
Fluorocyte method (Zdebik et al, 2008). Increased fluorescence means 
alkalinization. Unless indicated otherwise, extracellular solution contained 96 mM 
Cl- at pH 7.4. For 0 Cl-, gluconate replaced Cl-. Left traces in D and E are from 
the same oocyte, and center and right recording in E are from one oocyte as well. 
Similar results were obtained with at least 5 oocytes from 3 batches.  
 
Figure 2 Modulation of ClC-7/Ostm1 by anions, protons and temperature. (A)  
Relative anion conductance of oocyte-expressed rClC-7PM/Ostm1 in the 
presence of different extracellular anions (96 mM). Clamp protocol as in Figure 
1C. Mean ± s.e.m. of currents reached after 2 s at +80 mV were normalized to 
the current in Cl- for each oocyte (white bars) (Cl-, n=32 oocytes; Br-, n=7; NO3-, 
n=6; I-, n=5; gluconate (gluc-), n=5). Gray bar, NO3- conductance of rClC-
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7PM(S202P)/Ostm1 mutant measured and normalized as above (n=9). (B) 
Dependence of rClC-7PM/Ostm1 currents on pHo. I/V curves were obtained as in 
Figure 1B with currents normalized to those at pHo=7.4 and 80 mV. ≥ 6 oocytes 
per data point. (C) Left, typical voltage-clamp traces (top right, protocol) obtained 
at different pHo. Note different current scales that were chosen to normalize 
current amplitudes to the end of +80 mV pulse for better visualizing changes in 
activation kinetics. Right, τ was determined by single-exponential fit of the 80mV 
traces for ≥ 6 oocytes per pH value. Mean ± s.e.m. as function of pHo. (D) Typical 
voltage-clamp traces of rClC-7PM/Ostm1 (protocol as in C) at different 
temperatures, representative for 11 oocytes in which temperature was changed 
between 21°C to 29°C (n=8) and/or 37°C (n=9). 
 
Figure 3 Tail current analysis of ClC-7PM/Ostm1. (A) After activating HeLa cell-
expressed rClC-7PM/Ostm1 by pulses to +80 mV in whole-cell patch-clamp 
experiments, tail currents were measured at test voltages between -100 and 
+100 mV. Left, representative current traces (inset, clamp protocol). Right, I/V 
curve of ‘open exchanger’ obtained by extrapolation to the beginning of test 
pulses, shown together with ‘pseudo-steady-state’ currents measured after 2 s 
without preceding activation. Mean values ± s.e.m. normalized to the current at 
+80 mV of 8 (‘open exchanger’) and 19 (‘pseudo-steady-state’) cells. Error bars 
are mostly smaller than symbols. (B) Determination of nCl-/H+-exchange 
stoichiometry from reversal potentials of tail currents. HeLa cell-expressed rClC-
7PM/Ostm1 was clamped using a protocol as in A, but tail currents were 
measured at only three voltages close to reversal potentials (-20 to +20 mV, or 0 
to +40 mV). The contribution of endogenous currents was estimated by short 
pulses from -80 to 0 mV before activating ClC-7PM/Ostm1 (see Methods). [Cl-]o 
was shifted from 139 to 39 and/or 19 mM Cl- (top, representative traces from one 
cell) and pHo from 7.4 to 6.4 and/or 8.4. Bottom, reversal potentials corrected for 
background currents and liquid-junction potentials. Crosses, individual 
measurements. Filled circles and error bars, mean ± s.d. Lines, predictions for an 
nCl-/H+-exchanger with n=1, 2 and 3, and for a Cl--channel (1:0) under our 
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experimental conditions. Dashed lines in A and B, I=0. (C) Tail current analysis of 
hClC-7PM(R762Q)/Ostm1 expressed in HeLa cells to determine popen(V). Clamp 
protocol at bottom. (D) Apparent open probability popen as function of prepulse 
voltage, determined from tail currents as shown in (C). The line shows the fit by 
the Boltzman function popen = 1/(1 + exp(zn*e0(V½ - V)/kT)), which yielded zn= 
1.32 and V½ = 82 mV. Values are mean of 5 experiments. Error bars, s.e.m. 
 
Figure 4 Domains of Ostm1 that interact with ClC-7. (A) When transfected into 
HeLa cells, Ostm1-GFP localizes to the ER, CD4-GFP mostly to the plasma 
membrane, and a GFP-tagged CD4 chimera containing the TMD of Ostm1 
(COC-GFP) to the ER and plasma membrane. (B) When co-transfected with HA-
tagged rClC-7, Ostm1-GFP and COC-GFP, but not CD4-GFP, co-localized with 
rClC-7-HA (immuno-labelled for the HA epitope) to late endosomes/lysosomes 
(marked by immuno-labelling for LAMP-1). (C) Statistical analysis of lysosomal 
targeting of Ostm1, CD4 or chimeras thereof expressed either without (-) or with 
(+) rClC-7-HA assayed as in A and B. In the 3-letter abbreviations, C means CD4, 
O Ostm1, in the sequence extracytosolic N-terminal part, TMD, and cytoplasmic 
C-terminus. Means of 3-4 independent experiments with >100 cells each 
evaluated. Error bars, s.e.m. Constructs containing the TMD of Ostm1 localized 
to lysosomes upon co-expression with rClC-7. (D) Typical current traces of 
Xenopus oocytes co-expressing rClC-7PM with Ostm1, CD4, or CD4/Ostm1 
chimeras. Expression of significant currents required the presence of both the N-
terminus and TMD of Ostm1. Similar results were obtained with at least 10 
oocytes of at least 3 batches.  
 
Figure 5 Characterization of osteopetrosis-causing mutations in human ClC-7. 
(A) Position of analyzed dominant and recessive osteopetrosis-causing 
mutations (solid and open stars, respectively) in a CLC topology model (Dutzler 
et al, 2002). Mutations yielding no currents shown in purple (when retained with 
Ostm1-GFP in the ER of HeLa cells) and red (when exported from the ER), those 
with apparently normal currents in green, and those with accelerated activation in 
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blue (see C, D and Supplementary Figure S5). (B) Close-up of X-ray structure of 
CmClC (Feng et al, 2010) displaying the location of ClC-7 residues that 
accelerate gating when mutated. Except for L213 (corresponding to L174 in 
CmClC), the depicted ClC-7 residues are not identical to those of CmClC at 
these positions (R286, P619, R762 and R767 of hClC-7 correspond to L241, 
R532, V680 and S685, respectively, in CmClC) (Feng et al, 2010). The 
transmembrane part of one subunit is shown in gray, CBS2 and the linker to 
CBS1 of that subunit in red and yellow, respectively. Green helices at left are 
from the second subunit of the homodimer. (C) Representative current traces of 
hClC-7PM (‘WT’ or selected osteopetrosis-causing mutants) upon expression with 
Ostm1 in Xenopus oocytes. Mutants yielded either no or very low currents 
(R526W and L490F), apparently normal currents (S744F), or displayed 
accelerated activation (R762Q). (D) Subcellular localization of hClC-7 and 
selected mutants co-expressed with Ostm1-GFP in HeLa cells. Cells were 
immuno-labelled for hClC-7 and LAMP-2. In most cases, hClC-7 co-localized 
with Ostm1-GFP to LAMP-2-positive structures in addition to localizing to ER-like 
structures. However, hClC-7(R526W) remains with Ostm1-GFP in the ER 
(highlighted by nuclear envelope staining). In cells with a clear excess of Ostm1-
GFP (asterisk), it predominantly localizes to the ER.  
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MATERIALS AND METHODS 
 
Expression constructs and antibodies. For expression of untagged proteins in 
cell culture, constructs were subcloned into pcDNA3 or pcDNA3.1(+) (both 
Invitrogen). Constructs for rat ClC-7 in this vector have been described 
previously (Stauber & Jentsch, 2010). The construct for expression of 
fluorescently tagged Ostm1 in the pEGFP-N3 vector (Clontech) linking Ostm1 at 
the C-terminus with green fluorescent protein (GFP) by the sequence 
VDGTAGPGSIAT has been described (Stauber & Jentsch, 2010). To generate 
chimeric constructs between Ostm1 and CD4, the DNA sequences encoding the 
amino-terminal part (aa 1-286 for Ostm1 and aa 1-397 for CD4), the 
transmembrane region (estimated by hydrophobicity; aa 287-309 for Ostm1 and 
aa 398-420 for CD4) and the carboxy-terminal region (aa 310-338 for Ostm1 and 
aa 421-458 for CD4) of the respective protein were combined by recombinant 
PCR and cloned into pEGFP-N3.  
Constructs for heterologous expression in Xenopus oocytes were cloned into 
pTLN (Lorenz et al, 1996). For the surface expression assay (below), an HA 
epitope was inserted between residues E168 and K169 (extra-cytosolic loop 
between helices B and C) of hClC-7. Point mutations were introduced by PCR. 
For the G796fs mutation of hClC-7, the 3’UTR until the new stop codon was 
added. All constructs were confirmed by sequencing the complete ORF. 
Primary antibodies were mouse anti-LAMP-1, -LAMP-2 (both DSHB; clones 
H4A3 and H4B4, respectively) and -HA epitope (Covance, clone HA.11), rat anti-
HA epitope (Roche, clone 3F10) and rabbit anti-ClC-7 (7N4B (Kornak et al, 
2001)). Secondary antibodies conjugated to AlexaFluor 488, 546 or 633 were 
from Molecular Probes, HRP-conjugated antibodies from Jackson 
ImmunoResearch.  
 
Voltage clamp, qualitative pHi determinations and surface expression 
assay in Xenopus laevis oocytes. Xenopus laevis oocytes were injected with 
cRNA (23 ng for ClC-7 constructs and additional 23 ng for Ostm1 or Ostm1/CD4 
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chimeras) which was transcribed with the mMessage Machine kit (Ambion) from 
pTLN (Lorenz et al, 1996). After three days incubation at 17°C, currents were 
measured using standard two-electrode voltage clamp (TEVC) employing 
TurboTEC amplifiers (npi electronic) and pClamp10.2 software (Molecular 
Devices). Measurements were performed at room temperature or, when 
specified, the temperature was regulated by a TC-344 Heater Controller (Warner).  
Oocytes were superfused with modified ND96 saline (96 mM NaCl, 2 mM K-
gluconate, 1.8 mM Ca-gluconate, 1 mM Mg-gluconate). pH was buffered with 5 
mM HEPES, Tris, MES or 10 mM phosphate as appropriate. Ion substitutions 
were done by replacing NaCl with equimolar amounts of NaNO3, NaI, NaBr or 
Na-gluconate. Proton transport activity was measured qualitatively by recording 
intracellular pH (pHi) changes exploiting the pH-sensitive fluorescence of BCECF 
(injected 10-30 min prior to the experiment) in the Fluorocyte (Zdebik et al, 2008). 
ClC-7/Ostm1 was activated by an extended depolarization to +80 mV for 10 s 
followed by 3 s hyperpolarization to -80 mV, with a holding potential of -30 mV 
using TEVC. Currents and fluorescence changes were recorded simultaneously 
with the pClamp10.2 software. 
To determine the temperature-dependence of activation rate constants R = 1/τ of 
ClC-7PM/Ostm1, only the first 250 ms of depolarization (+80 mV) were fitted to an 
exponential function, because we observed a slow component at 37°C that 
significantly adds to the activation at later times. This was also observed with 
uninjected oocytes. Q10 values were determined by Q10 = (R2/R1)10/(T2-T1), with R1 
and R2 being the activation rate constants at temperatures T1 (37°C ) and T2 
(21°C), respectively. 
Surface expression of HA-tagged ClC-7 protein was determined 3 days after 
cRNA injection by an immuno-chemiluminescence assay as described (Zerangue 
et al, 1999) with up to 20 oocytes per construct and experiment. 
 
Patch-clamp experiments. Whole-cell patch-clamp measurements on cultured 
cells used patch pipettes of 3-5 MΩ resistance were filled with (in mM) 110 CsCl, 
10 NaCl, 0.5 CaCl2, 1 EGTA, 2 MgATP, 40 HEPES, pH 7.2. The calculated free 
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Ca++ concentration was 180 nM. The bath solution contained (in mM) 130 NaCl, 
5 KCl, 1 MgCl2, 1 CaCl2, 10 glucose, 20 HEPES, pH 7.4 with NaOH. Osmolarity 
was adjusted with sucrose to 280-290 mosmol/l for the pipette solution and to 
300 mosmol/l for the extracellular solution. To alter Cl- and pH gradients, NaCl 
was replaced partially by Na-gluconate and pH was buffered with 20 mM Tris (pH 
8.4) or 20 mM MES (pH 6.4). Data were acquired with an EPC-10 double 
amplifier and Pulse software (HEKA).  
 
Tail current analysis. To measure ‘open exchanger’ currents, activation pulses 
of 1 s to +80 mV were applied followed by 500-ms test voltage steps of 20 mV 
from -100 to +100 mV. To determine reversal potentials, the length and voltage 
of the activation pulse were adjusted to yield similarly strong current amplitudes 
at different [Cl-]o and pHo values. Activation pulses were preceded by ‘control 
pulses’ of 50 ms to -80, -40 and 0 mV to estimate background currents and their 
reversal potentials. Test pulses were applied in 20-mV steps between 0 and +40 
or -20 and +20 mV. Reversal potentials of background currents (Erev,bg) and of tail 
currents (Erev,meas) were determined by intrapolation. Reversal potentials of ClC-
7PM/Ostm1 (Erev,ClC-7) were then calculated by  
     Erev,ClC-7 = (Erev,meas – (Erev,bg * (γbg/γtot))) / (1 – (γbg/γtot)) 
(where γbg is the background slope conductance and γtot is the total slope 
conductance at the test pulses) and corrected for liquid-junction potentials. The 
equation 
     Erev = -(RT/(m+n)F)* ln (([Cl]om * [H]in) / ([Cl]im * [H]on))  
(where R,T and F have the usual meaning) was used for reversal potential 
calculation for an mCl-/nH+-exchanger with different coupling ratios of m:n.  
To determine the voltage dependence of gating, we transfected HeLa cells with 
human ClC-7PM(R762Q) and Ostm1-GFP. Adding GFP to the C-terminus of 
Ostm1 did not change currents, but selecting for fluorescent cells increased the 
success rate of patch-clamping. Fits of mono-exponential functions to tail 
currents measured as in Figure 3C gave currents at the time of the voltage step. 
These values were corrected by subtracting mean currents of non-transfected 
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cells at +80 mV (the test voltage). These corrected currents were normalized to 
currents at +140 mV, and normalized currents were averaged from 5 
experiments. These data were fitted to a Boltzmann function of the form: 
     f(V) = 1/(1 + exp(zn*e0(V½ - V)/kT)), 
with e0 being the elementary charge, V the voltage, k the Boltzmann constant 
and T the temperature, to yield V½ (the voltage for half-maximal activation) and zn 
(the gating charge (or valence)). Apparent popen (Figure 3D) was obtained by 
normalization to obtain popen= 1 for V → ∞.   
 
Cell culture and immunofluorescence microscopy. Plasmid DNA encoding 
the respective construct(s) was transfected into HeLa or tsA201 cells using 
FuGENE6 (Roche). Cells were grown at 37°C for 24 to 48 h before patch-clamp 
experiments or fixation with 4% PFA in PBS for 15 min. For immunolabelling, 
cells were incubated with 30 mM glycine in PBS for 5 min and permeabilized with 
0.1 % saponin in PBS for 10 min. Both primary and AlexaFluor-coupled 
secondary antibodies were applied in PBS/0.05% saponin supplemented with 
3 % BSA. Images were acquired with an LSM510 laser scanning confocal 
microscope equipped with a 63x 1.4 NA oil-immersion lens (Zeiss). 
To evaluate ClC-7-dependent trafficking of Ostm1/CD4 chimeras to late 
endosomes/lysosomes, GFP-tagged chimeras were assayed by co-localization 
of GFP fluorescence with LAMP-1 immuno-labelling. For double-transfected cells, 
only those cells in which rClC-7-HA co-localized with LAMP-1 were considered. 
More than 100 cells were counted per construct and experiment. 3-4 
independent experiments were performed per construct, with the investigator 
blinded to the kind of chimera. 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1, related to Figure 1B,C and Figure 4: ClC-
7PM/Ostm1 currents in mammalian cells and Xenopus oocytes. (A) 
Representative current traces of hClC-7PM (‘WT’), hClC-7PM(E247A) and hClC-
7PM(E314A) obtained with a voltage-clamp protocol consisting of 20mV steps 
to voltages between -80 and +80 mV for 2 s (inset) from oocytes three days 
after co-injection with Ostm1; as shown for rClC-7 in Figure 1C. (B) Typical 
whole-cell current traces (voltage-step protocol in inset) of rClC-7PM/Ostm1 
expressed in HeLa and tsA201 cells, respectively. Note pronounced tail 
currents with 121 mM Cl- in the pipette solution. (C), Current-voltage curves 
(protocol as in (B)) of rClC-7PM co-expressed with Ostm1-GFP in HeLa cells in 
the presence and absence, respectively, of 2 mM ATP in the pipette. Values 
are mean current densities ± s.e.m. of 9 (with ATP) and 8 (without ATP) cells. 
(D), Current-voltage curve (protocol as in (B)) of rClC-7PM expressed with 
GFP or with Ostm1-GFP in HeLa cells. Non-transfected (n.t.) cells served as 
control. Mean current densities ± s.e.m. of 9 (rClC-7PM co-expressed with 
Ostm1-GFP; same cells as in (C) in the presence of ATP), 12 (rClC-7PM with 
GFP) and 10 (untransfected) cells.  
Supplementary Figure S2, related to Figure 4A-C: Ostm1 domains 
needed for ClC-7-dependent trafficking to lysosomes. HeLa cells were 
transfected with the five C-terminally GFP-tagged Ostm1/CD4 chimeras 
(COO, OCO, OOC, CCO and OCC; C for CD4 and O for Ostm1; the position 
in the name indicates N-terminal, trans-membrane and C-terminal domain, 
respectively) that are not shown in Figure 4A,B, either alone (A) or with rClC-
7-HA (B). Immunodetection as in Figure 4. Only Ostm1/CD4 chimeras 
containing the TMD of Ostm1 are carried to lysosomes. 
Supplementary Figure S3, related to Figure 4D: Partial plasma 
membrane localization of rClC-7PM irrespective of Ostm1/CD4 co-
expression in HeLa cells. HeLa cells were co-transfected with rClC-7PM and 
C-terminally GFP-tagged Ostm1/CD4 chimeras (three-letter code: C for CD4 
and O for Ostm1; the position in the name indicates N-terminal, trans-
2
membrane and C-terminal domain, respectively), and immunostained after 30 
h for ClC-7 and the lysosome marker protein LAMP-2. In all cases, rClC-7PM
was detected at the plasma membrane.  
Supplementary Figure S4, related to Figure 5: Localization of amino 
acids mutated in osteopetrosis in CLC structure. X-ray structure of CmClC 
(Feng et al, 2010) displaying the location of the osteopetrosis-causing ClC-7 
mutations analyzed in this study. The transmembrane core-forming parts of 
the two identical subunits are shown in gray, CBS1 in yellow and CBS2 in 
orange, using darker colors for one subunit. Positions in the structure are 
based on the published alignment (Feng et al, 2010) of ClC-7 with CmClC and 
are only shown in one subunit. Color code of mutants as in Figure 5A: purple, 
mutants that localize to the endoplasmic reticulum in hClC7/Ostm1; red, 
mutants showing no or strongly reduced currents in hClC-7PM/Ostm1; green, 
mutants with WT-like currents; blue, mutants with accelerated activation 
kinetics. 
Supplementary Figure S5, related to Figure 5: Analysis of additional 
CLCN7 mutations found in human osteopetrosis. (A) Typical current 
traces of Xenopus oocytes co-expressing the indicated mutants (in hClC-7PM) 
together with Ostm1. (B) Subcellular localization of the same mutant (but in 
hClC-7) upon co-expression with Ostm1-GFP in HeLa cells. Experiments 
were performed as in Figure 5C,D.  
Supplementary Figure S6, related to Figure 5: Expression level of 
osteopetrosis-causing mutations that yielded no currents. (A) 
Immunoblot showing the protein expression of hClC-7PM (‘WT’ or selected 
osteopetrosis-causing mutations, which yielded no currents upon expression 
in Xenopus oocytes but localized with Ostm1-GFP to lysosomes when 
expressed in the wildtype background in HeLa cells) three days after co-
injection of the respective cRNA with that of Ostm1. Whole-oocyte protein 
equivalent to 1.5 oocytes was probed on immunoblot with rabbit antibody 
against ClC-7 (7N4B, Kornak et al., 2001) and mouse antibody against -
tubulin (clone DM1A, Sigma). Signal detection used chemiluminescence and 
3
a camera system. (B) Signal intensities in immunoblots were quantified using 
the free software ImageJ and normalized to ‘WT’ after background 
subtraction. Mean values ± s.e.m. of three independent experiments are 
shown.  
Supplementary Video 1, related to Figure 5B: Localization of 
‘accelerating’ osteopetrosis mutations in the transmembrane-CBS 
interface.    
Rotation by 15° of a close-up of X-ray structure of  CmClC (Feng et al, 2010) 
seen from a different perspective as in Figure 5B to better visualize the 
proximity of ClC-7 residues that accelerate gating when mutated. The 
transmembrane part of one subunit is shown in light gray, CBS1 in yellow, 
and CBS2 in orange (or pink). Dark gray and red helices on the left 
correspond to transmembrane part and CBS2, respectively, of the attached 
second subunit of the homodimer. 
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